The global prenatal and newborn genetic testing market size reached US$ 5.3 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 11.2 Billion by 2028, exhibiting a growth rate (CAGR) of 13.3% during 2022-2028. The growing demand for advanced diagnostic and screening devices, rising prevalence of congenital malformations and genetic abnormalities in newborn babies around the world, and thriving medical industry represent some of the key factors driving the market.
Prenatal and newborn genetic testing comprises blood tests, a specific type of ultrasound, and prenatal cell-free DNA screening that offers invaluable insights into the genetic makeup of unborn babies and newborns. It can identify certain birth defects, many of which are genetic disorders in unborn or newborn babies. It provides critical information to expectant parents, healthcare professionals, and researchers, enabling them to make informed decisions about the health and well-being of infants. It assists in improving patient outcomes and guiding medical interventions while enabling accurate identification of genetic variations and abnormalities during pregnancy and early infancy. It also aids in detecting various congenital conditions, such as Down syndrome, cystic fibrosis, sickle cell disease, and phenylketonuria. As it helps analyze various protein levels in the blood of parents to determine the risk for abnormal chromosome numbers in babies, the demand for prenatal and newborn genetic testing is rising across the globe.
Prenatal and newborn genetic testing comprises blood tests, a specific type of ultrasound, and prenatal cell-free DNA screening that offers invaluable insights into the genetic makeup of unborn babies and newborns. It can identify certain birth defects, many of which are genetic disorders in unborn or newborn babies. It provides critical information to expectant parents, healthcare professionals, and researchers, enabling them to make informed decisions about the health and well-being of infants. It assists in improving patient outcomes and guiding medical interventions while enabling accurate identification of genetic variations and abnormalities during pregnancy and early infancy. It also aids in detecting various congenital conditions, such as Down syndrome, cystic fibrosis, sickle cell disease, and phenylketonuria. As it helps analyze various protein levels in the blood of parents to determine the risk for abnormal chromosome numbers in babies, the demand for prenatal and newborn genetic testing is rising across the globe.
Prenatal and Newborn Genetic Testing Market Trends:
At present, the rising demand for advanced diagnostic and screening devices among the masses across the globe represents one of the key factors supporting the growth of the market. In addition, there is an increase in the prevalence of congenital malformations and genetic abnormalities in newborn babies worldwide. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the growing demand for non-invasive prenatal screening methods due to their various benefits, such as high accuracy and precision, less pain, and fast diagnosis, as compared to conventional methods, is positively influencing the market. Besides this, the rising awareness among individuals about the benefits of prenatal and newborn genetic testing is offering lucrative growth opportunities to industry investors. Additionally, the escalating demand for prenatal and newborn genetic testing due to the increasing number of health-conscious individuals is contributing to the growth of the market. Apart from this, governing agencies of various countries are focusing on improving healthcare infrastructure to provide enhanced healthcare services to citizens. In line with this, key players are developing genetic eye tests to identify the risk of keratoconus and other corneal dystrophies in patients. Furthermore, the growing demand for cell-free DNA in maternal plasma tests to detect the risk of genetic disorders is offering a favorable market outlook.Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global prenatal and newborn genetic testing market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product type, screening, disease, and end user.Product Type Insights:
- Consumables
- Instruments
Screening Insights:
- Non-invasive Prenatal Testing
- Chorionic Villus Sampling
- Amniocentesis
- Maternal Serum Screening
Disease Insights:
- Downs Syndrome
- Phenylketonuria
- Cystic Fibrosis
- Sickle Cell Anemia
End User Insights:
- Hospital
- Maternity and Specialty Clinics
- Diagnostic Centers
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global prenatal and newborn genetic testing market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, BGI Group, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Ravgen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report:
- How has the global prenatal and newborn genetic testing market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global prenatal and newborn genetic testing market?
- What is the impact of each driver, restraint, and opportunity on the global prenatal and newborn genetic testing market?
- What are the key regional markets?
- Which countries represent the most attractive prenatal and newborn genetic testing market?
- What is the breakup of the market based on the product type?
- Which is the most attractive product type in the prenatal and newborn genetic testing market?
- What is the breakup of the market based on the screening?
- Which is the most attractive screening in the prenatal and newborn genetic testing market?
- What is the breakup of the market based on the disease?
- Which is the most attractive disease in the prenatal and newborn genetic testing market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the prenatal and newborn genetic testing market?
- What is the competitive structure of the global prenatal and newborn genetic testing market?
- Who are the key players/companies in the global prenatal and newborn genetic testing market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Prenatal and Newborn Genetic Testing Market
6 Market Breakup by Product Type
7 Market Breakup by Screening
8 Market Breakup by Disease
9 Market Breakup by End User
10 Market Breakup by Region
11 Drivers, Restraints, and Opportunities
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- BGI Group
- Bio-Rad Laboratories Inc.
- F. Hoffmann-La Roche AG
- Illumina Inc.
- Laboratory Corporation of America Holdings
- Natera Inc.
- PerkinElmer Inc.
- Quest Diagnostics Incorporated
- Ravgen Inc.
- etc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | November 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 5.3 Billion |
| Forecasted Market Value ( USD | $ 11.2 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
